Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.

Discussion and conclusions Results from this phase III trial of sunitinib vs IFN- α showed that sunitinib was superior to IFN- α , based on a longer duration of median PFS; overall survival was also longer with sunitinib than with IFN- α , although the difference did not reach statistical significance ( Motzer et al , 2009 ).

also in 111,027 other papers